

Increasing SOE Export Potential: Bio Farma Encouraged Achievement of Export Sales 2018

Bandung (9/12). Bio Farma continued to meet export targets, estimated export sales until 2018 could reach USD 71.6 million. Vaccines to be exported in September to December consisted of Polio, Measles, TT, DTP, Td, for developing countries such as Pakistan, Afghanistan, Sudan, Morocco and other countries.

Rahman Roestan, President Director of Bio Farma, said when checking export readiness, today, September 12th, 2018 in Bandung.

"The final product of vaccines is distributed through UNICEF International institutions, PAHO; and through Bilateral in the form of bulk vaccines or intermediate products that will later be formulated and packaged into final vaccine products. Some manufacturers who buy bulk include five vaccine manufacturers in India, one in South Africa and one in Bangladesh. The types of bulk exported are bulk polio, tetanus, diphtheria, pertussis, measles," Rahman said.

"Currently the Bio Farma export market has two segments, namely procurement through UNICEF International agencies, Pan American Health Organization (PAHO), and through Bilateral, direct purchases from several vaccine manufacturers abroad such as India, Egypt, as well as several agents or distributors in South Africa, Thailand, Turkey, Mexico and other countries."

"We continue to coordinate with several international institutions, in early October 2018, Bio Farma is invited by UNICEF at the annual meeting of the vaccine industry, in Copenhagen, Denmark, which aims to update information on needs and forecasting for vaccine supply in the next 5 years, what products are needed in the world now and 10 years ahead."

"In addition, it is also to update international regulatory aspects, and Bio Farma meets directly with customers to get feedback on the needs and estimate Bio Farma's vaccine supply capability," Rahman added.

In the future Bio Farma will continue to prepare vaccine research to meet global needs, as on September 13th, Bio Farma also holds a National Life Science Research Forum (FRLN). A forum formed since 2011 synergy with Ministry of Research and Technology Higher Education, Research Institutions, Universities and the Ministry of Health, which aims to develop new vaccines and Life Science products in the country for national research self-reliance.

Twelve consortia and research Working Groups, namely Human Immunodeficiency Virus (HIV), Hepatitis B, Human Papillomavirus (HPV), Stem Cell, Erythropoetin (EPO), Tuberculosis (TB), Dengue Fever, Influenza, Malaria, Rotavirus, Pneumococcus and Delivery System. Hopefully the results of this research and development can be immediately had by the community and to achieve self-reliance.

Currently only around 30 vaccine manufacturers have obtained qualifications from the World Health Organization (WHO), one of them is Bio Farma. "We are the largest in Southeast Asia in terms of product type and capacity, as well as being a center of excellence reference for vaccine manufacturers in Islamic states. As an SOE, it has a very strategic role to participate in accelerating the development of the pharmaceutical industry and medical devices, in an effort to accelerate and self-reliance of the development of biopharmaceutical and vaccine products.

"With a total production capacity of more than 2 billion doses per year. The production composition

is 60 percent each for domestic needs and 40 percent for export needs.

About Bio Farma

Bio Farma is a state-owned manufacturer of Vaccines and Antisera, currently developing into a Life science company, established on August 6th, 1890. For 128 years of establishment Bio Farma has contributed to improving the quality of life of the nation, both in Indonesia and abroad. More than 140 countries have used Bio Farma Vaccine products, especially developing countries, and 50 of them are countries that are members of the Organization of Islamic Cooperation (OIC).

With a production capacity of more than 2 billion doses per year, it is the largest in Southeast Asia. Bio Farma has fulfilled the needs of National vaccines, including the need for vaccines for Pilgrims of Hajj and Umrah, as well as world vaccine needs through WHO and UNICEF.

With the philosophy Dedicated to Improve Quality of Life, Bio Farma plays an active role in increasing the availability and self-reliance of vaccine production in developing countries and Islamic countries to safeguard global health security. Further information www.biofarma.co.id

_

For media information, you can contact:

Nurlaela Arief

Head of Corporate Communications Dept.

Bio Farma

Email: lala@biofarma.co.id

Mobile: 081910102649: 62 22 2033755

www.biofarma.co.id

Bio Care: 1500810